We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

87 hedge funds and large institutions have $51.1M invested in Outlook Therapeutics in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more capital invested

Capital invested by funds: $29.7M → $51.1M (+$21.4M)

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

55% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 20

6% more funds holding

Funds holding: 82 → 87 (+5)

0.04% more ownership

Funds ownership: 0.53% → 0.57% (+0.04%)

Holders
87
Holders Change
+5
Holders Change %
+6.1%
% of All Funds
1.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
31
Reduced
20
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.57M
2
State Street
State Street
Massachusetts
+$998K
3
Squarepoint
Squarepoint
New York
+$343K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$250K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$188K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$507K
2
N
Nuveen
North Carolina
-$350K
3
VF
Vista Finance
Missouri
-$237K
4
GCP
GSA Capital Partners
United Kingdom
-$107K
5
Citadel Advisors
Citadel Advisors
Florida
-$98.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
IAMOG
76
Investors Asset Management of Georgia
Georgia
$17.4K – – –
TCA
77
Transcend Capital Advisors
New Jersey
$17.4K – – –
Fidelity Investments
78
Fidelity Investments
Massachusetts
$15.7K +$6.11K +224 +99%
MLICM
79
Metropolitan Life Insurance Company (MetLife)
New York
$14.9K – – –
UBS Group
80
UBS Group
Switzerland
$8.76K -$5.56K -204 -45%
TRCT
81
Tower Research Capital (TRC)
New York
$8.04K -$25.8K -946 -80%
LFG
82
Larson Financial Group
Missouri
$3.48K – – –
HI
83
Harbour Investments
Wisconsin
$2.26K – – –
PWMG
84
Prestige Wealth Management Group
New Jersey
$2.17K – – –
HFS
85
Hantz Financial Services
Michigan
$1K – – –
NC
86
NewSquare Capital
Pennsylvania
$348 – – –
S
87
SignatureFD
Georgia
$113 +$82 +3 New
VF
88
Vista Finance
Missouri
– -$237K -10,882 Closed
GCP
89
GSA Capital Partners
United Kingdom
– -$107K -4,892 Closed
Citadel Advisors
90
Citadel Advisors
Florida
– -$98.8K -4,533 Closed
SG Americas Securities
91
SG Americas Securities
New York
– -$68K -3,097 Closed
Fisher Asset Management
92
Fisher Asset Management
Washington
– -$13.6K -624 Closed
CB
93
CNB Bank
Pennsylvania
– -$10.9K -500 Closed
PVH
94
Psagot Value Holdings
Israel
– -$3K -141 Closed
1 2 3
4

OTLK Hedge Fund Activity: Q2 2023 in Review

87 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2023, worth a combined $51.1M — up 72% from $29.7M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new OTLK positions and 7 closed out — a net gain of 5 holders — while 31 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $1.57M. The largest seller was Millennium Management, cutting an estimated $507K.

  • 87 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2023, up from 82 in Q1 2023.
  • Funds reported $51.1M of Outlook Therapeutics stock for Q2 2023, up 72% quarter-over-quarter.
  • 12 funds opened new Outlook Therapeutics positions in Q2 2023 and 7 closed out, a net change of +5 holders.
  • The largest Outlook Therapeutics buyer in Q2 2023 was BlackRock, an estimated $1.57M added.
  • The largest Outlook Therapeutics seller in Q2 2023 was Millennium Management, an estimated $507K sold.

Based on aggregated 13F filings for Q2 2023.